Aarti Pharmalabs Ltd

Aarti Pharmalabs Ltd has announced the closure of its trading window for dealing in the company's securities. This closure is in compliance with SEBI (Prohibition of Insider Trading) Regulations, 2015. The trading window will be shut from Wednesday, July 01, 2026, and will reopen 48 hours after the declaration of the financial results for the quarter ending June 30, 2026. All designated and connected persons have been informed. The date of the board meeting to approve these results will be communicated separately.

Aarti Pharmalabs Ltd's Board of Directors approved the audited financial results for the quarter and financial year ended March 31, 2026. The company reported revenue from operations (net) of ₹179,755.17 lakhs for FY26. A final dividend of ₹2 per equity share was recommended. Smt. Ketki D. Visariya was re-appointed as the Cost Auditor and Manish Modi & Associates as the Internal Auditor for FY 2026-27. Mr. Sachin Patil and Mr. Rajendra Pagare were designated as Senior Management Personnel.

Aarti Pharmalabs Ltd's board approved the audited financial results for the quarter and financial year ended March 31, 2026. The company reported revenue from operations (net) of ₹1797.55 million and a net profit of ₹176.2 million for FY26. A final dividend of ₹2 per equity share of face value ₹5 each was recommended, subject to shareholder approval. Smt. Ketki D. Visariya was re-appointed as Cost Auditor and Manish Modi & Associates as Internal Auditor for FY 2026-27. Mr. Sachin Patil and Mr. Rajendra Pagare were designated as Senior Management Personnel.

Aarti Pharmalabs Ltd's Board of Directors, in its meeting held on May 25, 2026, approved the audited financial results for the quarter and financial year ended March 31, 2026. The board recommended a final dividend of ₹2 per equity share of face value ₹5 each, subject to shareholder approval. Additionally, Smt. Ketki D. Visariya was re-appointed as Cost Auditor and Manish Modi & Associates as Internal Auditor for FY 2026-27. Mr. Sachin Patil and Mr. Rajendra Pagare were designated as Senior Management Personnel.

Aarti Pharmalabs Ltd's board approved the audited financial results for the quarter and financial year ended March 31, 2026. The company reported revenue from operations (net) of ₹1797.55 million and a net profit of ₹176.2 million for the year ended March 31, 2026. The board recommended a final dividend of ₹2 per equity share of face value ₹5 each. Smt. Ketki D. Visariya was re-appointed as Cost Auditor and Manish Modi & Associates as Internal Auditor for FY 2026-27. Mr. Sachin Patil and Mr. Rajendra Pagare were designated as Senior Management Personnel.

Aarti Pharmalabs Ltd. announced the grant of 57,600 stock options to eligible employees of the company and its subsidiary under the APL Performance Stock Option Plan 2023 (PSOP 2023). The grant was approved by the Nomination and Remuneration Committee of the Board of Directors on May 25, 2026. The exercise price is set at ₹5 per option, subject to the Securities and Exchange Board of India (Share Based Employee Benefits and Sweat Equity) Regulations, 2021.

Aarti Pharmalabs Ltd's board approved the audited financial results for the year ended March 31, 2026. The company reported revenue from operations (net) of ₹1797.55 million for FY26. The board recommended a final dividend of ₹2 per equity share of face value ₹5 each, subject to shareholder approval. Smt. Ketki D. Visariya was re-appointed as Cost Auditor and Manish Modi & Associates as Internal Auditor for FY 2026-27. Mr. Sachin Patil and Mr. Rajendra Pagare were designated as Senior Management Personnel.

Aarti Pharmalabs Ltd has rescheduled its Board Meeting from May 18, 2026, to May 25, 2026. The meeting will address matters previously announced on May 11, 2026. The trading window will remain closed until 48 hours after the declaration of financial results, i.e., until May 27, 2026.

Aarti Pharmalabs Ltd has scheduled a Board of Directors meeting on May 18, 2026, to consider and approve the audited financial results for the quarter and financial year ended March 31, 2026. The board will also consider recommending a final dividend, if any, for the financial year ended March 31, 2026. The trading window, which has been closed since April 1, 2026, will remain closed until May 20, 2026.

Aarti Pharmalabs Ltd. is participating in the 'Saksham Niveshak' campaign initiated by the Investor Education and Protection Fund Authority (IEPFA), Ministry of Corporate Affairs. The campaign, which runs from April 01, 2026 to July 09, 2026, aims to create awareness among shareholders about unpaid or unclaimed dividends and facilitate their settlement. Shareholders are encouraged to update their KYC details and claim their unpaid dividends to prevent unwarranted transfers to the IEPFA. The campaign also intends to ensure proactive shareholder engagement, expedite dividend processing, and facilitate direct settlement of claims by the Company.